VYNE receives Nasdaq bid price deficiency notice; 180-day cure period to March 2026

VYNE Therapeutics Inc.

Closing bid price of VYNE common stock below $1.00 for 30 consecutive business days.
180-day compliance period until March 10, 2026; stock continues trading on Nasdaq Capital Market.
Compliance regained if bid price closes at $1.00+ for 10 consecutive trading days before deadline.
Company evaluating options; may seek second 180-day period if not compliant by March 10, 2026.
Failure to regain compliance could result in delisting of common stock.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.